Profil bibliographique

Vi K. Chiu

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

48Publications signalées

3407Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

Colorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersChemokine receptors and signalingCell Adhesion Molecules Research

Les publications récentes

Accès ouvert 2026 article OpenAlex

Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy

Gaurav Sharma, Yasmine Baca, Sanjay Goel, Anthony F. Shields et autres

us (code pays fourni par la source)

0 citations npj Precision Oncology

2026 conference-abstract OpenAlex

Clinical impact of chemotherapy and immune checkpoint inhibitor treatment in high-risk stage II and III colorectal cancer patients with dMMR/MSI-H and/or TMB-H status.

Vi K. Chiu, E M Saiz Lou, Adele Lerolle-Chiu

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2025 article OpenAlex

Effect of chemotherapy treatment on immunotherapy efficacy in colorectal cancer (CRC) patients with high microsatellite instability (MSI-H) and/or tumor mutational burden (TMB-H).

Vi K. Chiu, Adele Lerolle-Chiu

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2025 article OpenAlex

The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy

Jae‐Hyun Park, Min Thura, Vi K. Chiu, Brian Vicuna et autres

us, sg, cn (code pays fourni par la source)

1 citation Cell Reports Medicine

Accès ouvert 2024 article OpenAlex

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis et autres

us (code pays fourni par la source)

34 citations Journal of Clinical Oncology

2024 article OpenAlex

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Timothy Lewis Cannon, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer et autres

us (code pays fourni par la source)

23 citations Journal of Clinical Oncology

2024 conference-abstract OpenAlex

Abstract 5181: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Ari J. Rosenberg, Shumei Kato, Daniel Johnson, Aron Popovtzer et autres

us, il (code pays fourni par la source)

2 citations Cancer Research

2024 conference-abstract OpenAlex

Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Kathleen J. Yost, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer et autres

us (code pays fourni par la source)

1 citation Journal of Clinical Oncology

2024 conference-abstract OpenAlex

Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Tareq Al Baghdadi, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2023 article OpenAlex

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Nitin Rohatgi, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer et autres

us (code pays fourni par la source)

2 citations JCO Precision Oncology

2023 article OpenAlex

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

Herbert L. Duvivier, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer et autres

us (code pays fourni par la source)

43 citations Journal of Clinical Oncology

Accès ouvert 2023 conference-abstract OpenAlex

A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).

Samuel J. Klempner, Bassam Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis et autres

us (code pays fourni par la source)

14 citations Journal of Clinical Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.